Literature DB >> 31645219

Midterm Follow-up of Fenestrated and Scalloped Physician-Modified Endovascular Grafts for Zone 2 TEVAR.

Lucien Chassin-Trubert1, Marcello Mandelli2, Baris Ata Ozdemir1, Pierre Alric1, Thomas Gandet1, Ludovic Canaud1.   

Abstract

Purpose: To investigate the midterm outcomes of scalloped or fenestrated physician-modified endovascular grafts (PMEGs) for zone 2 thoracic endovascular aortic repairs (TEVAR). Materials and
Methods: Between November 2013 and May 2019, 54 consecutive patients (mean age 63 years; 41 men) were treated with thoracic PMEGs modified with 7 scallops or 47 fenestrations for the left subclavian artery (LSA). Indications for aortic repair were acute complicated type B aortic dissection (17, 31%), degenerative aneurysm (13, 24%), acute traumatic rupture of the aortic isthmus (9, 16%), post chronic dissection aneurysmal evolution (8, 15%), penetrating aortic ulcer (3, 6%), intramural hematoma (2, 4%), and floating thrombus (2, 4%).
Results: Technical success was 94%; 3 (6%) LSAs were unintentionally covered. An intraoperative type Ia endoleak was treated during the index procedure. One (2%) patient suffered spinal cord ischemia, with irreversible bilateral paraplegia. Three (6%) patients experience postoperative minor strokes with full neurological recovery. Four (7%) patients died in the perioperative period; 2 (2%) were due to aneurysm rupture. Mean follow-up was 26±16 months; 15 (28%) patients had at least 3 years of follow-up. Two (4%) type II endoleaks were identified and successfully treated (4% reintervention rate); no other endoleaks were identified. All the LSAs remained clinically and radiologically patent. There were no conversions to open repair, ruptures, retrograde dissection, stent fracture, migrations, or other aortic complications.
Conclusion: Scalloped or single-fenestrated PMEGs for the LSA appear to be durable and safe in the midterm. Combined with low periprocedural morbidity and mortality, these results suggest that this approach can be considered as an off-label alternative to extend proximal seal to zone 2 for TEVAR. Further studies with a larger number of patients and long-term outcomes are needed to fully validate this approach.

Entities:  

Keywords:  aortic arch; endograft; fenestrated stent-graft; left subclavian artery; physician-modified endovascular grafts; scallop; stent-graft; supra-aortic branches; thoracic aorta; thoracic endovascular aortic repair

Year:  2019        PMID: 31645219     DOI: 10.1177/1526602819881128

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  5 in total

1.  Physician-Modified Endovascular Grafts for Zone-2 Thoracic Endovascular Aortic Repair.

Authors:  André B Queiroz; Jackson B Lopes; Vanessa P Santos; Pedro B A F Cruz; Ronald J R Fidelis; José S Araújo Filho; Luiz C S Passos
Journal:  Aorta (Stamford)       Date:  2022-05-31

Review 2.  Narrative review on endovascular techniques for left subclavian artery revascularization during thoracic endovascular aortic repair and risk factors for postoperative stroke.

Authors:  Mario D'Oria; Kevin Mani; Randall DeMartino; Martin Czerny; Konstantinos P Donas; Anders Wanhainen; Sandro Lepidi
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

3.  Early and Mid-Term Outcomes of Open versus Endovascular Left Subclavian Artery Debranching for Thoracic Aortic Diseases.

Authors:  Philip Dueppers; Lorenz Meuli; Benedikt Reutersberg; Michael Hofmann; Florian Messmer; Alexander Zimmermann
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-12-22       Impact factor: 1.889

4.  Clinical Validation of the Impact of Branch Stent Extension on Hemodynamics in ISF-TEVAR Involving LSA Reconstruction.

Authors:  Jiateng Hu; Fengshi Li; Peng Qiu; Xiaoyu Wu; Hongji Pu; Zhen Zhao; Jinbao Qin; Guang Liu; Shanliang Jin; Xinwu Lu; Xiaobing Liu
Journal:  Front Cardiovasc Med       Date:  2022-06-13

Review 5.  Role of Endoluminal Techniques in the Management of Chronic Type B Aortic Dissection.

Authors:  Konstantinos Spanos; Tilo Kölbel
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-29       Impact factor: 2.740

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.